Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sohm Inc (OP: SHMN )

0.0009 UNCHANGED
Streaming Delayed Price Updated: 12:41 PM EDT, Apr 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Sohm Inc

< Previous 1 2 3 Next >
SOHM, Inc. Announces Patent Allowance/Approval in South Korea
Via ACCESS Newswire
SOHM, Inc. Shares an Exciting Expansion and Upcoming Presentation on ABBIE
Via ACCESS Newswire
SOHM, Inc. Launches New AI Team to Advance ABBIE System and Genome Editing Innovations
Via ACCESS Newswire
SOHM, Inc. Shares Groundbreaking Findings in ABBIE Technology
Via ACCESS Newswire
SOHM, Inc. Announce Dr. Wei Zhu Onboard as Senior Marketing and Sales Consultant
Via ACCESSWIRE
SOHM, Inc. has Received ABBIE Technology Kits' Pre-Launch Pre-Orders
Via ACCESSWIRE
Rheumatoid Arthritis Patients Face Heightened Risk of Depression, Study Finds
Via Investor Brand Network
Why Prescription Drugs Can Be Costly
Via Investor Brand Network
SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japan's Patent Office (特許庁, Tokkyochō, JPO) Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinant-Organisms, -Cells, -Secretomes, -Exosomes
Via ACCESSWIRE
SOHM, Inc. Announce Dr. David Zarling Onboard as Senior Product Development Advisor
Via ACCESSWIRE
SOHM, Inc. Continues to Build its IP Portfolio in the Gene Editing and Cell Engineering Space
Via ACCESSWIRE
SOHM, Inc., Announce Dr. Tetsuya Kawamura Ph. D. Joined as a Cell Engineer and Biochemist
Via ACCESSWIRE
SOHM, Inc. has signed the Manufacturing and Supply of Skincare Topical Products with New Export Customers
Via ACCESSWIRE
SOHM, Inc., Announce a New Collaboration and Joins Forces with Stanford University
Via ACCESSWIRE
SOHM, Inc. Announces its ABBIE Genome Editing Technology Successfully Engineered a T-cell immunotherapy from a Healthy Human Donor
Via ACCESSWIRE
BioMedNewsBreaks — SOHM, Inc. (SHMN) Continues to Advance Groundbreaking Technology
Via Investor Brand Network
InvestorNewsBreaks – SOHM, Inc. (SHMN), Coastar Therapeutics Collaborate to Advance Field of Genome Editing
Via Investor Brand Network
FDA Grants Florida Permission to Import More Affordable Medicines from Canada
Via Investor Brand Network
Exposures Product Safety
Small Study Shows Existing Drug Could Reduce Opioid Administration After Surgery
Via Investor Brand Network
New Compound Promises Greater Efficacy Against Pain, Has No Side Effects
Via Investor Brand Network
BioMedNewsBreaks– SOHM Inc. (SHMN) Announces Filing of Provisional Patent for ABBIE Smart Gene Editing Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
SOHM Files Provisional Patent on ABBIE’s ‘Smart Gene-Editing’ That Uses Latest Enzymes and Guide RNA to Resolve Off-Target Gene-Editing Limitations
From SOHM, Inc.
Via GlobeNewswire
FDA Announces Changes to Safety Labeling Requirements for Opioid Medications
Via Investor Brand Network
Exposures Product Safety
SOHM Inc. (SHMN) Releases New Product Line and Expands Manufacturing Operations in Carlsbad, California
Via Investor Brand Network
BioMedNewsBreaks — Why SOHM Inc. (SHMN) Is ‘One to Watch’
Via Investor Brand Network
Senate Committee Hears How Drug Shortages Impact Patients
Via Investor Brand Network
SOHM Inc.’s (SHMN) New Gene-Editing Technology Holds Potential to Revolutionize the Field of Cardiology, With Superior Capabilities Over Other Gene-Editing Systems
Via Investor Brand Network
SOHM Inc. (SHMN) Taps into UACI’s Robust Resources and Specialized Infrastructure for ABBIE Advancement
Via Investor Brand Network
BioMedNewsBreaks – SOHM, Inc. (SHMN) Announces 2024 Outlook for Business Units
Via Investor Brand Network
SOHM Announces Business Outlook for 2024
From SOHM, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.